{"id":"atezolizumab-injection-tecentriq","safety":{"commonSideEffects":[{"rate":"20–30","effect":"Fatigue"},{"rate":"15–25","effect":"Decreased appetite"},{"rate":"10–20","effect":"Nausea"},{"rate":"10–15","effect":"Cough"},{"rate":"10–15","effect":"Dyspnea"},{"rate":"3–5","effect":"Immune-mediated pneumonitis"},{"rate":"2–4","effect":"Immune-mediated hepatitis"},{"rate":"1–3","effect":"Immune-mediated colitis"},{"rate":"5–10","effect":"Hypothyroidism"}]},"_chembl":{"chemblId":"CHEMBL3707227","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atezolizumab binds to programmed death ligand 1 (PD-L1), preventing its interaction with PD-1 and B7.1 receptors on T cells. This blockade restores T-cell activation, proliferation, and anti-tumor function. By inhibiting the PD-L1/PD-1 axis, the drug enhances the body's natural immune response against cancer cells.","oneSentence":"Atezolizumab is a monoclonal antibody that blocks PD-L1 on tumor and immune cells, releasing the brakes on T-cell-mediated anti-tumor immunity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:47.399Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer (NSCLC)"},{"name":"Metastatic urothelial carcinoma"},{"name":"Small cell lung cancer (SCLC)"},{"name":"Hepatocellular carcinoma"},{"name":"Breast cancer (triple-negative)"},{"name":"Gastric cancer"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tecentriq","RO5541267"],"phase":"marketed","status":"active","brandName":"Atezolizumab Injection [Tecentriq]","genericName":"Atezolizumab Injection [Tecentriq]","companyName":"Nykode Therapeutics ASA","companyId":"nykode-therapeutics-asa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atezolizumab is a monoclonal antibody that blocks PD-L1 on tumor and immune cells, releasing the brakes on T-cell-mediated anti-tumor immunity. Used for Metastatic non-small cell lung cancer (NSCLC), Metastatic urothelial carcinoma, Small cell lung cancer (SCLC).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}